SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (5578)10/21/1998 5:40:00 PM
From: sim1  Read Replies (1) | Respond to of 6136
 
AG1766 from their web site...

Third Generation Protease Inhibitor
Agouron has acquired rights to develop and commercialize a novel HIV protease inhibitor (AG1776) discovered by Japan Energy Corporation, Tokyo, Japan. Data from preclinical trials presented at the 12th World AIDS conference in Geneva by Japan Energy demonstrate significant in vitro potency and an encouraging cross-resistance
profile. Agouron plans to initiate clinical studies later in 1999.



To: Izzy who wrote (5578)10/21/1998 6:14:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 6136
 
Izzy:

The shareholder's meeting is delayed until December. SEC stuff. See Margie's post.

As you may remember, I've largely stopped following technical stuff at the company. I was assuming that 1766 was the JE molecule. Regardless, no, it won't be on the market during '99.

Rick


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News